Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999656 | Urologic Oncology: Seminars and Original Investigations | 2015 | 4 Pages |
Abstract
Nearly two-thirds of patients on AS experienced a decrease in eGFR and nearly one-fourth had upstaging of CKD classification. The annual eGFR decline experienced by patients on AS minimally exceeded the annual decline of 1.49±0.3 ml/min/1.73 m2 that an individual who was 70 to 79 years of age can expect from aging alone. Further follow-up is necessary to assess this in a more definitive manner, but this trend should be considered when evaluating AS as an alternative to interventional therapies for SRM.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Crystal V. M.D., Matthew R. B.S., Julia B. M.D., Arindam Ph.D., Andrew A. M.D., Peter M.D., Phillip M. M.D., Mohamad E. M.D., James M. M.D.,